Physician profile
Tina Thomas
NPI 1659627248
$2,055.69
in general payments reported to CMS, 2019-2025
19 companies · $176 in 2025
The $176 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $583 · 2020: $188 · 2021: $238 · 2022: $263 · 2023: $433 · 2024: $175 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $770 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $770.17 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $680.31 | 2019-2025 | Veltassa, Korsuva |
| Astrazeneca Pharmaceuticals LP | $382.23 | 2019-2025 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $307.63 | 2019-2024 | Velphoro |
| Otsuka America Pharmaceutical, INC. | $74.70 | 2019-2025 | Jynarque |
| Opko Pharmaceuticals, LLC | $63.92 | 2019 | |
| Amgen INC. | $60.51 | 2019-2021 | |
| Akebia Therapeutics INC | $59.45 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.83 | 2024-2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $48.62 | 2021-2023 | Lupkynis |
| Travere Therapeutics, INC. | $41.77 | 2019-2025 | |
| Glaxosmithkline, LLC. | $38.90 | 2023-2025 | Benlysta |
| Bayer Healthcare Pharmaceuticals INC. | $38.83 | 2021-2023 | |
| Genzyme Corporation | $36.39 | 2019 | |
| Alnylam Pharmaceuticals INC. | $36.38 | 2021-2022 | |
| Calliditas Therapeutics US INC. | $34.89 | 2023-2024 | Tarpeyo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $34.43 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $30.62 | 2025 | |
| Lilly USA, LLC | $20.58 | 2023 | Jardiance |
| Horizon Therapeutics Plc | $15.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tina Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.